Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ROS1 positive
i
Other names:
ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, V-Ros Avian UR2 Sarcoma Virus Oncogene Homolog 1, C-Ros Oncogene 1 Receptor Tyrosine Kinase, Proto-Oncogene Tyrosine-Protein Kinase ROS, Proto-Oncogene C-Ros-1, MCF3, ROS, V-Ros UR2 Sarcoma Virus Oncogene Homolog 1 (Avian), ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, Transmembrane Tyrosine-Specific Protein Kinase, Receptor Tyrosine Kinase C-Ros Oncogene 1, C-Ros Receptor Tyrosine Kinase, Proto-oncogene C-Ros, C-Ros-1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
6098
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
TPX-0005
Sensitive: B - Late Trials
IASLC-TTLC 2023 - 5 days (New C3)
TPX-0005
Sensitive
:
B
IASLC-TTLC 2023 - 5d
TPX-0005
Sensitive: B - Late Trials
IASLC-TTLC 2023 - 5 days
TPX-0005
Sensitive
:
B
IASLC-TTLC 2023 - 5 days - (New C3)
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
lorlatinib
Sensitive: A2 - Guideline
lorlatinib
Sensitive
:
A2
lorlatinib
Sensitive: A2 - Guideline
lorlatinib
Sensitive
:
A2
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
ceritinib
Sensitive: A2 - Guideline
ceritinib
Sensitive
:
A2
ceritinib
Sensitive: A2 - Guideline
ceritinib
Sensitive
:
A2
ROS1 positive
Lung Cancer
ROS1 positive
Lung Cancer
lorlatinib
Sensitive: C2 – Inclusion Criteria
lorlatinib
Sensitive
:
C2
lorlatinib
Sensitive: C2 – Inclusion Criteria
lorlatinib
Sensitive
:
C2
ROS1 positive
Solid Tumor
ROS1 positive
Solid Tumor
TQ-B3101
Sensitive: C2 – Inclusion Criteria
TQ-B3101
Sensitive
:
C2
TQ-B3101
Sensitive: C2 – Inclusion Criteria
TQ-B3101
Sensitive
:
C2
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
AB-106
Sensitive: C2 – Inclusion Criteria
AB-106
Sensitive
:
C2
AB-106
Sensitive: C2 – Inclusion Criteria
AB-106
Sensitive
:
C2
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
brigatinib
Sensitive: C2 – Inclusion Criteria
brigatinib
Sensitive
:
C2
brigatinib
Sensitive: C2 – Inclusion Criteria
brigatinib
Sensitive
:
C2
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
TQ-B3101
Sensitive: C2 – Inclusion Criteria
TQ-B3101
Sensitive
:
C2
TQ-B3101
Sensitive: C2 – Inclusion Criteria
TQ-B3101
Sensitive
:
C2
ROS1 positive
Mesothelioma
ROS1 positive
Mesothelioma
APG-2449
Sensitive: C2 – Inclusion Criteria
APG-2449
Sensitive
:
C2
APG-2449
Sensitive: C2 – Inclusion Criteria
APG-2449
Sensitive
:
C2
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
APG-2449
Sensitive: C2 – Inclusion Criteria
APG-2449
Sensitive
:
C2
APG-2449
Sensitive: C2 – Inclusion Criteria
APG-2449
Sensitive
:
C2
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
TQ-B3139
Sensitive: C3 – Early Trials
TQ-B3139
Sensitive
:
C3
TQ-B3139
Sensitive: C3 – Early Trials
TQ-B3139
Sensitive
:
C3
ROS1 positive
Solid Tumor
ROS1 positive
Solid Tumor
TPX-0005
Sensitive: C3 – Early Trials
TPX-0005
Sensitive
:
C3
TPX-0005
Sensitive: C3 – Early Trials
TPX-0005
Sensitive
:
C3
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
ensartinib
Sensitive: C3 – Early Trials
ensartinib
Sensitive
:
C3
ensartinib
Sensitive: C3 – Early Trials
ensartinib
Sensitive
:
C3
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
ROS1 inhibitor
Sensitive: C3 – Early Trials
ROS1 inhibitor
Sensitive
:
C3
ROS1 inhibitor
Sensitive: C3 – Early Trials
ROS1 inhibitor
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login